United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET

Company Participants

Dewey Steadman - Head of Investor Relations
Martine Rothblatt - Chairperson and Chief Executive Officer
Michael Benkowitz - President and Chief Operating Officer
James Edgemond - Chief Financial Officer and Treasurer
Leigh Peterson - Executive Vice President-Product Development and Xenotransplantation

Conference Call Participants

Terence Flynn - Morgan Stanley
Roanna Ruiz - Leerink
Ash Verma - UBS
Joseph Thome - TD Cowen

Operator

Good morning and welcome to the United Therapeutics Corporation First Quarter 2024 Earnings Webcast. My name is Danielle and I will be your conference operator today. All participants on the call portion of this webcast will be in listen-only mode until the question-and-answer portion of the earnings call. [Operator Instructions] Please note this call is being recorded.

I will now turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics.

Dewey Steadman

Thank you, Danielle and good morning. It's my pleasure to welcome you to the United Therapeutics Corporation's first quarter 2024 earnings webcast. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements will involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties, and we assume no obligation to update forward-looking statements.

Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products and these remarks are intended solely to educate investors and are not intended to serve as the basics for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. And full prescribing information for the products are available on our website.

Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; Dr. Leigh Peterson, our Executive Vice President, Product Development and Xenotransplantation and Pat Poisson, our Executive Vice President of Technical Operations.

Note that Pat Poisson and I will present in a fireside chat session and one-on-one meetings at the Goldman Sachs Global Healthcare Conference on June 12 in Miami. Also, our scientific, medical and commercial teams will present at the American Thoracic Society International Conference May 17 through the 22nd in San Diego; The Seventh World Symposium on Pulmonary Hypertension, June 29 to July 1st in Barcelona and the Pulmonary Hypertension Association's 2024 International PH Conference and Scientific Sessions, August 15 to 18th in Indianapolis.